Trial Profile
A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Palifosfamide (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Registrational; Therapeutic Use
- Acronyms PICASSO-3; PICASSO-III
- Sponsors Alaunos Therapeutics
- 12 Sep 2016 Primary endpoint (Overall survival) has not been met according to the results published in the Journal of Clinical Oncology.
- 12 Sep 2016 Results published in the Journal of Clinical Oncology.
- 26 Mar 2013 Status changed from active, no longer recruiting to discontinued, according to a ZIOPHARM Oncology media release.